Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on